Tin and fatty acids in dementia

Corrigan, Frank M.; Rhijn, A. G. Van; Ijomah, G.; McIntyre, F.; Skinner, E. R.; Horrobin, David F.; Ward, Neil

doi:10.1016/0952-3278(91)90035-4

Cited by 35 publications

(12 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were observed in the frontal cortex, which is important for reasoning, attention, planning and emotions [63,[65][66][67][68][69]. Nevertheless, other studies did not show any modification of DHA content of the frontal cortex [70][71][72][73] or in other brain regions that are also implicated in AD, such as the temporal or parietal lobes and the parahippocampus [62,[66][67][70][71]74]. In accordance with animal studies, it has been recently proposed that an altered composition of lipid rafts in human frontal cortex, including a decrease in their DHA content, may be related to the neuropathology of AD, especially the formation of senile plaques [68,69].…”

Section: Post-mortem Brain Studiessupporting

confidence: 83%

Challenges to determining whether DHA can protect against age-related cognitive decline

Hennebelle

Harbeby²,

Tremblay

et al. 2015

Clinical Lipidology

View full text Add to dashboard Cite

DHA, an omega-3 fatty acid, is an important constituent of brain membranes and has a key role in brain development and function. This review aims to highlight recent research on DHA's role during age-related cognitive decline and Alzheimer's disease. Animal and in vitro studies have provided some interesting mechanistic leads, especially on brain glucose metabolism, that may be involved in neuroprotection by DHA. However, results from human studies are more mitigated, perhaps due to changing DHA metabolism during aging. Recent innovative tools such as 13 C-DHA for metabolic studies and 11 C-DHA for PET provide interesting opportunities to study factors that affect DHA homeostasis during aging and to better understand whether and how to use DHA to delay or treat Alzheimer's disease.

show abstract

Section: Post-mortem Brain Studiessupporting

confidence: 83%

Challenges to determining whether DHA can protect against age-related cognitive decline

Hennebelle

Harbeby²,

Tremblay

et al. 2015

Clinical Lipidology

View full text Add to dashboard Cite

show abstract

“…A trend toward lower levels of vitamin D and zinc also was observed [25]. Plasma levels of other nutrients and vitamins have been reported low in AD compared with age-matched healthy individuals (i.e., u-3 polyunsaturated fatty acids [PUFAs] [26][27][28][29] and selenium [30,31]). Reduced uridine has been reported in the CSF of patients with mild AD [32], whereas a trend toward lower plasma uridine levels in mild AD compared with healthy controls has been reported for the first time in a recent study [33].…”

Section: Lower Micronutrients and Fatty Acid Status In Admentioning

confidence: 76%

Nutritional approaches in the risk reduction and management of Alzheimer's disease

Wijk

Cansev

et al. 2013

Nutrition

View full text Add to dashboard Cite

“…13 However, other studies focusing on dementia not only reported no difference in DHA in plasma cholesterol esters and phospholipids, 14 but also reported significantly higher DHA in plasma phospholipids 15 or cholesteryl esters. 16, 17 Hence, results of studies examining the association between blood FA and cognitive performance have been inconsistent.…”

Section: Introductionmentioning

confidence: 99%

Serum docosahexaenoic and eicosapentaenoic acid and risk of cognitive decline over 10 years among elderly Japanese

et al. 2014

View full text Add to dashboard Cite

Background/Objectives:To clarify the association of serum docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) levels with cognitive decline over 10 years.Subjects/Methods:This study was part of the National Institute for Longevity Sciences - Longitudinal Study of Aging, and was conducted with 232 male and 198 female Japanese community-dwelling subjects aged 60–79 years in the second wave (2000–2002). Cognitive function was assessed with the Mini-Mental State Examination (MMSE) in both the second and seventh (2010–2012) waves. Fasting venous blood samples were collected in the morning, and serum DHA and EPA levels were measured. Multiple logistic regression analysis was performed among participants with an MMSE score ⩾24 in the second wave (n=430) to estimate the odds ratio (OR) and 95% confidence interval (CI) for MMSE score ⩽23 or MMSE score decline ⩾4 10 years later. These estimates were based on baseline tertiles of serum DHA or EPA levels, and controlled for age, sex, education, MMSE score at baseline, alcohol consumption, current smoking, body mass index and disease history.Results:Fifteen (3.5%) subjects whose MMSE score was ⩽23 and 36 (8.3%) subjects whose MMSE score declined to ⩾4 showed cognitive decline. Multivariate-adjusted OR (95% CI) for the lowest through highest tertiles of serum DHA to MMSE score ⩽23 or decline⩾4 were 1.00 (reference), 0.11 (0.02–0.58) and 0.17 (0.04–0.74), or 1.00 (reference), 0.22 (0.08–0.61) and 0.31 (0.12–0.75), respectively (P for trend=0.01 or 0.04). Serum EPA was not associated with cognitive decline.Conclusions:The study gives some indication that a moderately high level of serum DHA might prevent cognitive decline among community-dwelling elderly Japanese individuals.

show abstract

Tin and fatty acids in dementia

Cited by 35 publications

References 16 publications

Challenges to determining whether DHA can protect against age-related cognitive decline

Challenges to determining whether DHA can protect against age-related cognitive decline

Nutritional approaches in the risk reduction and management of Alzheimer's disease

Serum docosahexaenoic and eicosapentaenoic acid and risk of cognitive decline over 10 years among elderly Japanese

Contact Info

Product

Resources

About